Phase II Trial of Ibrutinib and PD-1 Blockade in High Risk Chronic Lymphocytic Leukemia to Improve Immune Dysfunction
Phase of Trial: Phase II
Latest Information Update: 15 Apr 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 10 Apr 2019 Status changed from not yet recruiting to recruiting.
- 01 Apr 2019 Planned initiation date changed from 1 May 2019 to 1 Jun 2019.
- 21 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 May 2019.